4SC strengthens patent protection for its epigenetic cancer drug in China

17-Aug-2015 - Germany

4SC AG announced that it has further strengthened the patent protection for its epigenetic anti-cancer compound 4SC-202 - a selective inhibitor of LSD1 and HDACs 1, 2, and 3 - in China.

The Chinese Intellectual Property Office (SIPO) has granted a patent relating to the tosylate salt of the compound. As this salt has been used in the clinical trials with 4SC-202, this patent provides a further building block in 4SC's global protection strategy for the drug candidate. The patents for 4SC-202 tosylate salt will provide additional protection against potential competitors and thus complements the composition of matter patents for 4SC-202, which so far have been granted in 61 countries, including patents in the major markets USA, Europe, China, Japan, Russia, and India.

Other news from the department research and development

Most read news

More news from our other portals

Last viewed contents

ViGeneron closes of series A financing to drive development of next generation gene therapy pipeline

ViGeneron closes of series A financing to drive development of next generation gene therapy pipeline

Heptares enters a research and drug discovery collaboration with Juntendo University

Novasep and instrAction enter a worldwide strategic alliance for non-chiral chromatography

Kedrion and ProMetic Form Strategic Alliance to Develop Orphan Drugs from Plasma

Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent

QIAGEN and ActiveSight Sign Co-Marketing Agreement Targeting Protein Crystallography

U.S. Development Partner Quest Diagnostics Completes Clinical Development of Septin9 Colorectal Cancer Blood Test

Global Pharmaceutical companies expect hard price competition in the rising Biosimilars segment - Bi-annual survey among more than 80 executives from globally active pharmaceutical companies based in 16 countries and spread over four continents

Metobolomics uncovers key indicators of nonalcoholic fatty liver disease - Impaired oxidation in liver associated with progression to NASH

Converting carbon dioxide into useful chemicals with the help of bacteria and solar power - How electrolysis and fermentation can be combined in one system

Converting carbon dioxide into useful chemicals with the help of bacteria and solar power - How electrolysis and fermentation can be combined in one system

Agilent Technologies Presents Thought Leader Award to Lipidomics Expert Dr. Jules Griffin - Cambridge Researcher to Further Studies of Obesity, Fatty Liver Disease

3D images display plant organs down to the smallest detail - Intelligent software for a better understanding of plant tissue development

3D images display plant organs down to the smallest detail - Intelligent software for a better understanding of plant tissue development